Table 3.

Competing risk analyses (Fine-Gray model) for calprotectin and hs-CRP, and amputation and MACE1 in PAD patients (n = 317).

	Calprotectina (µg/mL)			hs-CRPa (mg/L)
	SHR	95% CI	p	SHR	95% CI	p
Amputation
Unadjusted	2.49	1.54–4.04	<0.001	1.76	1.48–2.09	<0.001
Model 1	2.56	1.56–4.19	<0.001	1.82	1.52–2.20	<0.001
Model 2	2.62	1.58–4.34	<0.001	1.70	1.42–2.05	<0.001
Model 3	2.57	1.58–4.17	<0.001	1.74	1.47–2.07	<0.001
MACE1
Unadjusted	1.56	1.03–2.35	0.034	1.53	1.35–1.75	<0.001
Model 1	1.70	1.14–2.54	0.009	1.48	1.28–1.70	<0.001
Model 2	1.74	1.17–2.58	0.006	1.46	1.28–1.66	<0.001

Sub-Hazard ratios (SHR) are effect sizes for a doubling of serum calprotectin and hs-CRP. Amputation models were adjusted as follows; Model 1: sex, age. Model 2: diabetes mellitus, dyslipidemia and Model 3: hypertension and estimated glomerular filtration rate (eGFR). Major adverse cardiovascular events 1 (MACE1, including amputation and CV-death) models were adjusted as follows; Model 1: sex, age. Model 2: diabetes mellitus, hypertension, dyslipidemia, eGFR. ^aLogarithmically transformed variable.